Ibuprofen safely dampens inflammatory markers in 28-patient drug-resistant tuberculosis trial. The Experimental Tuberculosis Unit (UTE) at the Germans Trias i Pujol Research Institute (IGTP) has published in Nature Communications the results of a phase IIa pilot clinical trial assessing ibuprofen as a host-directed therapy in patients with pre-extensively drug-resistant tuberculosis (pre-XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: The Experimental Tuberculosis Unit (UTE) at the Germans Trias i Pujol Research Institute (IGTP) has published in Nature Communications the results of a phase IIa pilot clinical trial assessing ibuprofen as a host-directed therapy in patients with pre-extensively drug-resistant tuberculosis (pre-XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).
- Ponto de atenção: ibuprofen.
- Ponto de atenção: safely.
- Ponto de atenção: dampens.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
